Related references
Note: Only part of the references are listed.High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
Tiziano Barbui et al.
LEUKEMIA (2021)
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Francesca Palandri et al.
BLOOD CANCER JOURNAL (2021)
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Donna Przepiorka et al.
ONCOLOGIST (2020)
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Madan Jagasia et al.
BLOOD (2020)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease
Robert Zeiser et al.
BLOOD ADVANCES (2020)
A life-threatening ruxolitinib discontinuation syndrome
Giacomo Coltro et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Yan Beauverd et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2011)
Share Paper
